Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
CRBU Stock Chart & Stats
$1.66
-$0.16(-8.56%)
At close: 4:00 PM EST
$1.66
-$0.16(-8.56%)
Day’s Range― - ―
52-Week Range$0.66 - $3.54
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.20M
Market Cap
$160.77M
Enterprise Value-$40.88M
Total Cash (Recent Filing)$147.26M
Total Debt (Recent Filing)$25.46M
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Mar 16, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding93,468,040
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.57
Price to Sales (P/S)14.37
P/FCF Ratio-0.99
Enterprise Value/Market Cap-0.25
Enterprise Value/Revenue-4.40
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$8.40Price Target Upside406.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash ReservesCaribou's cash reserves at the end of the quarter are expected to support operations into the second half of 2027.
Competitive PositioningThe efficacy results for CB-010 in the ANTLER trial are comparable to those of FDA-approved CAR-T therapies, suggesting strong competitive positioning.
Financial PerformanceCaribou's financial results showed a net loss per share that was better than previous estimates, indicating improved financial performance.
Bears Say
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.66 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $160.77M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 16, 2026 which is in 80 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.354 by $0.054.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 93,468,040 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.354. Following the earnings report the stock price went down -12.389%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.40 (406.02% Upside)
$8.40 (406.02% Upside)
Hedge Fund Trend
Increased
By 5.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 22.4%
Last 30 Days ▲ 22.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
-74.28%
Trailing 12-Months
Asset Growth
-40.77%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.40
▲(406.02% Upside)
Technical Analysis
Sangamo Biosciences
―
Cellectis SA
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
8.00% Insiders
6.35% Mutual Funds
14.09% Other Institutional Investors
64.54% Public Companies and
Individual Investors